Subgroups
Bayer AG (Holding Company)
-
Thursday - May 10, 2012
Award from the Bayer Cares Foundation for innovative health projects
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care" » more
-
Friday - April 27, 2012
Annual Stockholders' Meeting 2012 » more
-
Friday - April 27, 2012
Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders’ Meeting of Bayer AG:
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1 » more
-
Thursday - April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed » more
-
Monday - April 2, 2012
20 percent increase in energy efficiency achieved head of time:
Bayer makes rapid progress in Green IT » more
-
Wednesday - March 14, 2012
“Meet Management” investor conference:
Bayer sets ambitious targets for 2014
Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position » more
-
Tuesday - February 28, 2012
Financial News Conference
Full Year 2011 Results » more
-
Thursday - February 23, 2012
Elections to the Supervisory Board to be held at the Annual Stockholders’ Meeting on April 27, 2012
Werner Wenning to be proposed as Chairman of the Supervisory Board of Bayer AG
Dr. Manfred Schneider to remain in office until September 30, 2012 / Two candidates nominated for election as new stockholder representatives / Stockholders to resolve on a new compensation system for the members of the Supervisory Board » more
-
Thursday - February 23, 2012
Bayer plans dividend increase for 2011 to EUR 1.65 per share
Payout to rise by 10 percent to EUR 1,364 million » more
-
Tuesday - February 21, 2012
Bayer initiates global “Bee Care Program” to further promote bee health
“Bayer Bee Care Centers” to open in Europe and the USA » more
-
Friday - January 27, 2012
“Sustainability Yearbook 2012” listing globally top performers presented in Davos:
Bayer rated the most sustainable German company in its sector
One of just three chemical companies worldwide to receive Gold Class seal of quality from rating agency SAM » more
-
Tuesday - December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again » more
-
Monday - December 19, 2011
Employees donate over EUR 300,000 and company contributes a further EUR 400,000:
Bayer foundation provides EUR 700,000 for construction of children care facility in Japanese earthquake area
Home for orphans in Tohoku region / Bayer’s relief aid to Japan totals almost EUR 2.3 million » more
-
Monday - December 19, 2011
Awards from the Bayer Science & Education Foundation:
Bayer Early Excellence in Science Award 2011: EUR 30,000 for young research scientists
Dr. Cristobal Uauy (John Innes Centre in Norwich, Great Britain) wins the „Biology“ category / Dr. Andreas Bender (University of Cambridge, Great Britain) takes the „Chemistry“ award / Prof. Dr. Arne Thomas (Technical University Berlin) awarded prize in the „Materials“ field » more
-
Thursday - November 17, 2011
New edition of research, the Bayer scientific magazine
Innovations from the world of research at Bayer
Personalized medicine against cancer / Creating new active crop protection ingredients with biotechnology / Electric mobility: materials for the cars of the future » more
-
Wednesday - November 16, 2011
International Press Conference
„Perspective on Growth in Asia“ » more
-
Wednesday - November 16, 2011
“Perspective on Growth in Asia”
Bayer plans further expansion in Asia
Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai » more
-
Friday - November 4, 2011
Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke prevention in patients with atrial fibrillation / Rivaroxaban does not require routine coagulation monitoring, making it more convenient to both patients and physicians » more
-
Thursday - October 27, 2011
Bayer AG Third Quarter 2011 Results and News Conference Call » more
-
Thursday - October 27, 2011
After a good third quarter: Bayer confirms Group outlook
Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR 1,099 million / EBITDA before special items up by 8.5 percent to EUR 1,805 million / HealthCare and CropScience margins distinctly improved – MaterialScience weaker / Net income more than doubled to EUR 642 million (plus 125.3 percent) » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
